PIONEER III
Coronary Artery Disease
Amber Antos-Mellang | amber.antos@allina.com | 612-863-8098
The primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the XIENCE or Promus durable polymer coronary stents.
M. Nicholas Burke, MD
SINOMED / US Subsidiary: NOVA Vascular, LLC
Open/Enrolling